Negative-Positive Valence Domains in Anxiety and Depression
| Status: | Completed |
|---|---|
| Conditions: | Anxiety, Depression, Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 10/18/2017 |
| Start Date: | September 1, 2013 |
| End Date: | June 30, 2017 |
Latent Constructs: Negative-Positive Valence Domains in Anxiety and Depression
Anxiety and depression are highly prevalent and disabling conditions that frequently
co-occur, and are costly to the individual and society. Despite important advances in our
understanding of these disorders, there is a significant unmet need to identify reliable and
clinically useful tests that can predict prognosis, inform treatment choice for a given
individual, and improve treatment outcomes. The aim of this project is to fill this critical
gap by validating a battery of measures including brain imaging, psychophysiology, behavior,
and self-report that will reliably assess positive and negative affect, or valence, system
functioning in a broad sample of individuals screened for anxiety and depression as part of
their routine primary care visits.
co-occur, and are costly to the individual and society. Despite important advances in our
understanding of these disorders, there is a significant unmet need to identify reliable and
clinically useful tests that can predict prognosis, inform treatment choice for a given
individual, and improve treatment outcomes. The aim of this project is to fill this critical
gap by validating a battery of measures including brain imaging, psychophysiology, behavior,
and self-report that will reliably assess positive and negative affect, or valence, system
functioning in a broad sample of individuals screened for anxiety and depression as part of
their routine primary care visits.
Participants presenting to the UCSD and UCLA primary care clinics will be screened as part of
their routine visit using the Patient Health Questionnaire (PHQ-9) and Generalized Anxiety
Disorder 7 (GAD-7). Participants who call in will be asked to provide verbal informed consent
for phone screening and the IRB approved Screening Questionnaire and the Overall Anxiety
Severity and Impairment Scale (OASIS) will be administered.
Participants who remain eligible after the phone screening will be asked to return for a
Clinical Interview, Behavioral Session, Biomarker blood draw, (and optional genetics), and
Neuroimaging Session.
All participants will be contacted approximately 3-months later and invited to complete the
same battery of self-report measures completed during the baseline session (described below).
The self-report measures will be administered through a secure on-line survey database. This
data will allow investigators to (1) confirm that participants continue to meet initial
eligibility criteria and are therefore eligible for the full re-test battery and (2) use
baseline measures of positive and negative valence domains to predict changes in symptoms and
functioning.
A subset of 50 participants (n=25 from each UCSD and UCLA) will be randomly selected to
return approximately three months later to complete the same battery of assessments in the
Behavioral and Neuroimaging Sessions to establish test-retest reliability of the latent
constructs.
their routine visit using the Patient Health Questionnaire (PHQ-9) and Generalized Anxiety
Disorder 7 (GAD-7). Participants who call in will be asked to provide verbal informed consent
for phone screening and the IRB approved Screening Questionnaire and the Overall Anxiety
Severity and Impairment Scale (OASIS) will be administered.
Participants who remain eligible after the phone screening will be asked to return for a
Clinical Interview, Behavioral Session, Biomarker blood draw, (and optional genetics), and
Neuroimaging Session.
All participants will be contacted approximately 3-months later and invited to complete the
same battery of self-report measures completed during the baseline session (described below).
The self-report measures will be administered through a secure on-line survey database. This
data will allow investigators to (1) confirm that participants continue to meet initial
eligibility criteria and are therefore eligible for the full re-test battery and (2) use
baseline measures of positive and negative valence domains to predict changes in symptoms and
functioning.
A subset of 50 participants (n=25 from each UCSD and UCLA) will be randomly selected to
return approximately three months later to complete the same battery of assessments in the
Behavioral and Neuroimaging Sessions to establish test-retest reliability of the latent
constructs.
1. Positive for anxiety and/or depressive symptoms.
2. Score on the PHQ-9 and OASIS.
3. Between the ages of 18-55, inclusive.
4. Have signed informed consent document(s) indicating that participant understands the
purpose of and procedures required for the study and willing to participate in the
study.
5. Have sufficient proficiency in English language to understand and complete interviews,
questionnaires, and all other study procedures.
6. Have telephone or easy access to telephone.
7. History of brain injury with evidence of neurological deficits, neurological
disorders, or severe or unstable medical conditions that might be compromised by
participation in the study (to be determined by primary care provider).
8. Current and regular use of a medication that could affect brain functioning.
9. Must not have MRI contraindications such as: cardiac pacemaker, metal fragments in
eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary
artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal),
electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit),
persons who have ever been a metal worker/welder, history of eye surgery/eyes washed
out because of metal, inability to lie still on one's back for 60 minutes; prior
neurosurgery; tattoos with metal dyes, unwillingness to remove body piercings, and
pregnancy.
10. Intact or correctable vision and hearing.
We found this trial at
1
site
Click here to add this to my saved trials
